Navigation Links
Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
Date:3/10/2010

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK pathway, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in a Phase 3 trial, under Special Protocol Assessment (SPA), in multiple myeloma, with a Phase 3 trial in refractory metastatic colorectal cancer, under SPA, pending commencement, and in Phase 2 clinical development for several other tumor types. Keryx is also developing Zerenex™ (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is pending commencement under an SPA agreement with the FDA. Keryx is headquartered in New York City.

Media Contact: Lauren Fischer, Director of Investor Relations, Keryx Biopharmaceuticals, +1-212-531-5962,

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
2. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
3. Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
4. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
5. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
9. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
10. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
11. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014 Stryker Orthopaedics, the ... Champions Tour, is rounding out its debut year of ... Scottsdale, AZ. This marks the ... Champions Tour that the brand has activated on-site with ... educate golf fans on the importance of joint health.  ...
(Date:10/30/2014)... Oct. 30, 2014 Boston Scientific Corporation (NYSE: ... the 2014 Credit Suisse Annual Healthcare Conference on Tuesday, ... AZ.  Dan Brennan , executive vice president and ... company beginning at approximately 8:00 a.m. PT followed by ... webcast of the presentation and question and answer session ...
(Date:10/30/2014)... , Oct. 30, 2014 CVS Health (NYSE: ... new clinical affiliations with three leading regional health systems to ... The collaborating health systems include Baptist Health System in ... which include Commonwealth Health in Pennsylvania , ... Arizona , and Tennova Healthcare in Tennessee ...
Breaking Medicine Technology:Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 4Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 4
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... in Liberia -- one of three West African nations ravaged ... officials said Wednesday. Dr. Bruce Aylward, WHO,s assistant director ... burials in Liberia and no increase in laboratory-confirmed cases. He ... tame the epidemic may be making some progress, The ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Global prebiotics ... 2020, according to a new study by Grand View ... surging demand for sugar and fat free products owing ... the demand for prebiotics over the forecast period. , ... , Food & beverage was the largest application ...
(Date:10/30/2014)... The annual meeting of The ... close on Saturday, October 18th, marking the end of ... 1989. NAMS is North America’s leading non-profit organization dedicated ... all women during midlife and beyond through an understanding ... and thought leaders from fields as varied as gynecology, ...
(Date:10/30/2014)... News) -- Scientists who used stem cells to create ... could provide a new way to learn more about ... team used human pluripotent stem cells -- which can ... to grow the functional miniature stomachs, to study infection ... of ulcers and stomach cancer. The miniature stomachs ...
(Date:10/30/2014)... (HealthDay News) -- Eating a low-carb, high-fat diet could ... to new research. A review of five ... that focuses on foods like bacon, eggs, heavy cream, ... in adults whose condition doesn,t improve with medication. ... people with epilepsy whose seizures are not stopped by ...
Breaking Medicine News(10 mins):Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 3
... homeopathic alternative for reducing the symptoms related to ... without a prescription and without negative side effects. ... use in children ages 5 to 19 released ... from the Saint Louis University School of Medicine, ...
... European Mammography Systems Product Quality Leadership Award" ... of the exceptional quality of its Computed ... quality control, product performance, quality assurance programme ... http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )"In addition to being a ...
... women with recurrent breast cancer, the treatment the doctor chooses ... cancer. A group from Toronto has recently completed the world,s ... biopsy of suspected tumors that recurred elsewhere in the body. ... the women having a significant change in their treatment. In ...
... Colo., March 18 Keystone Symposia on Molecular and ... first HIV/AIDS meeting in 1984 when it convenes its ... " HIV Immunobiology: From Infection to Immune Control " ... than 850 scientists from around the world will attend.These ...
... City Council for passage of life-saving legislationNEW YORK, March ... nonprofit organization dedicated to finding a cure for life-threatening ... Department of Health and Mental Hygiene (DOHMH) to create ... among restaurant workers. In addition to working with ...
... medical conditions may not see any benefit from annual prostate cancer screening tests, according to results of a... ... Click here for more information. , , ... , , , , ... , , , ...
Cached Medicine News:Health News:ADD-care -- A Natural, Homeopathic Alternative Reducing Symptoms Related to Attention Deficit Disorder 2Health News:ADD-care -- A Natural, Homeopathic Alternative Reducing Symptoms Related to Attention Deficit Disorder 3Health News:Frost & Sullivan Recognises FUJIFILM Corporation's Outstanding Product Quality Leadership 2Health News:Frost & Sullivan Recognises FUJIFILM Corporation's Outstanding Product Quality Leadership 3Health News:Frost & Sullivan Recognises FUJIFILM Corporation's Outstanding Product Quality Leadership 4Health News:Research shows biopsy of recurrent breast cancer can alter treatment 2Health News:Keystone Symposia to Mark 25th Anniversary of its First HIV/AIDS Meeting 2Health News:Keystone Symposia to Mark 25th Anniversary of its First HIV/AIDS Meeting 3Health News:Food Allergy Initiative to Partner With NYC Department of Health on Educational Poster for Restaurants Citywide 2Health News:Food Allergy Initiative to Partner With NYC Department of Health on Educational Poster for Restaurants Citywide 3Health News:US trial shows no early mortality benefit from annual prostate cancer screening 2Health News:US trial shows no early mortality benefit from annual prostate cancer screening 3Health News:US trial shows no early mortality benefit from annual prostate cancer screening 4Health News:US trial shows no early mortality benefit from annual prostate cancer screening 5Health News:US trial shows no early mortality benefit from annual prostate cancer screening 6
... The CALBIOTECH INC. (CBI) Prolactin ELISA ... of prolactin in human serum or plasma. ... chain polypeptide hormone with a molecular weight ... is based on a solid phase direct ...
... hormone secreted in significant amounts by the ... in synergy with estrogen, plays an important ... of mammary gland growth and lactation in ... effects on cell growth in other tissues ...
... ADVIA Centaur delivers a new ... provides the flexibility to integrate ... now and in the future. ... comprehensive disease-focused menu of immunoassays ...
... The Anti-MPO - ELISA (P-ANCA) ... MPO antibodies using highly purified myeloperoxidase ... by contaminations like lactoferrin or elastase ... can not be detected by indirect ...
Medicine Products: